


FROM SUGHRUE MION PLLC DC

(TUE) 1. 7'03 15:46/ST. 15:46/NO. 4260759628 P 1
Washington, DC 20037-3213



T 202.293.7060
F 202.293.7860

www.sughrue.com

FAX

Date January 7, 2003

To Examiner Bruck KIFLE

Of PTO Group Art Unit 1624

Fax **703-746-5014**

From Drew Hissong

Subject Supplemental Amendment

Our Ref Q65078 Appln No 09/869,103

Conf No 9862 Inventors Masakazu SATO, et al.

Pages 14 (including cover sheet)

Please call attention to problems with this transmission by return fax or telephone. Thank you.

THE INFORMATION CONTAINED IN THIS COMMUNICATION IS CONFIDENTIAL, MAY BE ATTORNEY-CLIENT PRIVILEGED, AND IS INTENDED ONLY FOR THE USE OF THE ADDRESSEE. UNAUTHORIZED USE, DISCLOSURE OR COPYING IS STRICTLY PROHIBITED AND MAY BE UNLAWFUL. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY US.

This fax filing includes:

1. This cover sheet
2. SUPPLEMENTAL AMENDMENT

CERTIFICATION OF FACSIMILE TRANSMISSION

Sir:

I hereby certify that the above-identified correspondence is being facsimile transmitted to Examiner Bruck KIFLE at the Patent and Trademark Office on January 7, 2003, at 703-746-5014.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read 'Drew Hissong'.

Drew Hissong
Reg. No. 44,765

#8 C
PS

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q65078

Masakazu SATO, et al.

Appln. No.: 09/869,103

Group Art Unit: 1624

Confirmation No.: 9862

Examiner: KIFLE, B.

Filed: June 22, 2001

For: 20-HETE SYNTHASE INHIBITOR

SUPPLEMENTAL AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


This Supplemental Amendment is further to the Amendment Under 37 C.F.R. §1.111
filed in this application on November 21, 2002.

Please amend the above-identified application as follows:

IN THE CLAIMS:

Please enter the following amended claims:

5. (Twice amended) A hydroxyformamidine derivative represented by the formula:



wherein at least one of R¹¹ to R⁵⁵ represents a C₂₋₆ alkenyl group; a C₃₋₈ cycloalkyl C₁₋₆ alkyl group; a C₃₋₈ cycloalkyl group; a C₃₋₈ cycloalkoxy group; a C₁₋₆ hydroxyalkyl group; a C₁₋₆